ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
XING Mobility unveils IMMERSIO™ Matrix, an immersion-cooled marine battery system delivering twice the energy density and 3C discharge for electric vessels
XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...
XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...
Collaboration leverages Gemini Enterprise to onboard engineers up to three times fasterAMSTERDAM, June 11, 2026 /PRNewswire/ -- Google Cloud today announced a collaboration with Randstad...
Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North...
Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...
SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...